<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03524508</url>
  </required_header>
  <id_info>
    <org_study_id>NIFTY</org_study_id>
    <nct_id>NCT03524508</nct_id>
  </id_info>
  <brief_title>Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer</brief_title>
  <official_title>Randomized Phase II Trial of Fluorouracil and Folinic Acid With or Without Liposomal Irinotecan (ONIVYDE) for Patients With Metastatic Biliary Tract Cancer Which Progressed Following Gemcitabine Plus Cisplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhoon Yoo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ulsan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyungpook national university Chilgok hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of combination of
      fluorouracil/folinic acid and liposomal irinotecan(Onivyde) compared with fluoruracil/folinic
      acid in patients with metastatic biliary tract cancer which progressed on 1st line
      gemcitabine/cisplatin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter, open-label, randomized, phase II study comparing the efficacy
      and safety between fluorouracil/folinic acid plus liposomal irinotecan and
      fluoruracil/folinic acid monotherapy in patients with metastatic biliary tract cancer which
      progressed on 1st line gemcitabine/cisplatin.

      Eligible patients will be included in this study and treated according to the protocol. Study
      treatment will be continued until disease progression, unacceptable toxicity, or patient's
      decision/consent withdrawal. Local investigators will determine disease progression,
      radiologic or clinical deterioration.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>from the date of enrollment to the earlier of the date of confirmed progression or death from any cause. (assessed up to 36 months)</time_frame>
    <description>Progression-free survival is the time from the date of enrollment to the earlier of the date of confirmed progression or death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>from the date of enrollment to death from any cause. (assessed up to 36 months)</time_frame>
    <description>Overall survival is the time from the date of enrollment to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates determined by the investigator according to the RECIST(Response Evaluation Criteria in Solid Tumors) v1.1</measure>
    <time_frame>from the date of enrollment to end of treatment. (assessed up to 36 months)</time_frame>
    <description>The response rate is the proportion of eligible patients with measurable lesions with a overall response of CR(Complete Response) or PR(Partial Response)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC-QLQ (European Organization for Research and Treatment of Cancer - Quality of life Questionnaire) C30 (version 3.0)</measure>
    <time_frame>from the date of Screening to end of treatment. (assessed up to 36 months)</time_frame>
    <description>EORTC-QLQ C-30 questionnaires will be performed at screening visit, at pre-dose (Cycle 1 Day1) of every subsequent cycle, at the end of treatment visit. It is a 30‐item questionnaire. It has 4-point scales for the item number 1 to 28. These are coded with the same response categories as items 1 to 28, namely &quot;not at all=1&quot; &quot;a little=2&quot; &quot;quite a bit=3&quot; and &quot;very much=4&quot; It has 7-point scale for question number 29 to 30. These are coded with the same response categories as items 29 to 30, namely &quot;worst=1&quot; to &quot;best=7&quot; Total score will be minimum 30 and maximum 126.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>from the date of enrollment to 30 days after last treatment. (assessed up to 36 months)</time_frame>
    <description>Severity of adverse events will be graded by NCI-CTCAE (National Cancer Institute - Common Terminology Criteria for Adverse Events) v4.03</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">174</enrollment>
  <condition>Metastatic Biliary Tract Cancer</condition>
  <arm_group>
    <arm_group_label>5-FU/LV/Onivyde</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Onivyde 70 mg/m2 (90 minutes), leucovorin (LV) 400 mg/m2 (30 minutes), 5-FU 2400 mg/m2 (46 hours) IV every 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5FU/LV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>leucovorin (LV) 400 mg/m2 (30 minutes), 5-FU 2400 mg/m2 (46 hours) IV every 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Onivyde</intervention_name>
    <description>The recommended dose and regimen of Onivyde is 70 mg/m2 intravenously over 90 minutes, followed by leucovorin (LV) 400 mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 2 weeks.</description>
    <arm_group_label>5-FU/LV/Onivyde</arm_group_label>
    <other_name>Liposomal irinotecan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU/LV</intervention_name>
    <description>The recommended dose and regimen of leucovorin (LV) 400 mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 2 weeks</description>
    <arm_group_label>5-FU/LV/Onivyde</arm_group_label>
    <arm_group_label>5FU/LV</arm_group_label>
    <other_name>Fluorouracil/Folinic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and written informed consent form

          2. ≥ 19 years of age

          3. Histologically or cytologically confirmed cholangiocarcinoma

          4. Documented metastatic disease

          5. At least one measurable lesion according to the RECIST v1.1

          6. Disease progression on gemcitabine-cisplatin combination therapy

          7. For patients whose disease recurred after curative resection (R0 or R1), previous
             adjuvant 5-FU-based chemotherapy is allowed if there is at least 6 month-interval
             between the last dose of adjuvant chemotherapy and recurrence of disease.

          8. Adequate hepatic, renal and hematological function AST(Aspartate Aminotransferase),
             ALT(Alanine Aminotransferase) ≤ 100 IU/L (100 U/L), Cr(Creatinine) ≤ 1.5mg/dL

          9. Eastern Cooperative Oncology Group (ECOG) Performance status 0-1

        Exclusion Criteria:

          1. Serum total bilirubin ≥2 x ULN(upper limit of normal) (biliary drainage is allowed for
             biliary obstruction)

          2. Severe renal impairment (Clcr ≤ 30 ml/min)

          3. Inadequate bone marrow reserves as evidenced by:

               -  ANC(Absolute Neutrophile Count) ≤ 1,500 cells/μl; or

               -  Platelet count ≤ 100,000 cells/μl; or

               -  Hemoglobin ≤ 9 g/dL

          4. ECOG performance status 2-4

          5. Any clinically significant disorder impacting the risk-benefit balance negatively per
             physician's judgment

          6. Any clinically significant gastrointestinal disorder, including hepatic disorders,
             bleeding, inflammation, occlusion, or diarrhea &gt; grade 2

          7. Severe arterial thromboembolic events (myocardial infarction, unstable angina
             pectoris, stroke) in last 6 months

          8. NYHA(New York Heart Association) Class III or IV congestive heart failure, ventricular
             arrhythmias or uncontrolled blood pressure. Or known abnormal ECG with clinically
             significant abnormal findings

          9. Active infection or an unexplained fever &gt;38.5°C (excluding tumor fever), which in the
             physician's opinion might compromise the patient's health

         10. Current use or any use in last two weeks of strong CYP3A-enzyme inducers/inhibitors
             and/or strong UGT1A inhibitors

         11. Known hypersensitivity to any of the components of Onivyde other liposomal irinotecan
             formulations, irinotecan, fluoropyrimidines, or leucovorin.

         12. Breast feeding, known pregnancy, positive serum pregnancy test or unwillingness to use
             an effective method of contraception, during therapy and for 3 months following the
             last dose of Onivyde. Females of Childbearing Potential must either agree to use and
             be able to take effective contraceptive birth control measures (Pearl Index &lt; 1) or
             agree to practice complete abstinence from heterosexual intercourse during the course
             of the study and for at least 3 months after last application of program treatment. A
             female subject is considered to be of childbearing potential unless she is age ≥ 50
             years and naturally amenorrhoeic for ≥ 2 years, or unless she is surgically sterile.
             Males must agree not to father a child (including not donating sperm) during the
             course of the trial and for at least 6 months after last administration of study
             drugs.

         13. Previous treatment with combination drug tegafur, gimeracil, and oteracil potassium
             with seven days before enrollment.

         14. Current treatment with Sorivudine.

         15. Patients who are seriously debilitated or are suffering from bone marrow depression
             after radiotherapy or treatment with other antineoplastic agents.

         16. Pregnancy or women with child-bearing potential or lactating.

         17. Non-malignant disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changhoon Yoo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Changhoon Yoo</last_name>
    <phone>82-2-3010-1727</phone>
    <email>cyoo.amc@gmail.com</email>
  </overall_contact>
  <link>
    <url>http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020571s048lbl.pdf</url>
    <description>Camptosar® (irinotecan) U.S. Package Insert (Accessed 23 March 2016)</description>
  </link>
  <link>
    <url>https://www.medicines.org.uk/emc/medicine/21586</url>
    <description>Irinotecan hydrochloride Summary of Product Characteristics (Accessed 23 March 2016)</description>
  </link>
  <reference>
    <citation>Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.</citation>
    <PMID>26742998</PMID>
  </reference>
  <reference>
    <citation>Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010 Jun;17(6):1471-4. doi: 10.1245/s10434-010-0985-4.</citation>
    <PMID>20180029</PMID>
  </reference>
  <reference>
    <citation>Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010 Apr 8;362(14):1273-81. doi: 10.1056/NEJMoa0908721.</citation>
    <PMID>20375404</PMID>
  </reference>
  <reference>
    <citation>Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, Nagino M, Kondo S, Nagaoka S, Funai J, Koshiji M, Nambu Y, Furuse J, Miyazaki M, Nimura Y. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010 Aug 10;103(4):469-74. doi: 10.1038/sj.bjc.6605779. Epub 2010 Jul 13.</citation>
    <PMID>20628385</PMID>
  </reference>
  <reference>
    <citation>Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D; ESMO Guidelines Committee. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 Sep;27(suppl 5):v28-v37.</citation>
    <PMID>27664259</PMID>
  </reference>
  <reference>
    <citation>Kim BJ, Hyung J, Yoo C, Kim KP, Park SJ, Lee SS, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Park JH, Cho H, Ryoo BY, Chang HM. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients. Cancer Chemother Pharmacol. 2017 Jul;80(1):209-215. doi: 10.1007/s00280-017-3353-2. Epub 2017 Jun 8.</citation>
    <PMID>28597043</PMID>
  </reference>
  <reference>
    <citation>Fornaro L, Cereda S, Aprile G, Di Girolamo S, Santini D, Silvestris N, Lonardi S, Leone F, Milella M, Vivaldi C, Belli C, Bergamo F, Lutrino SE, Filippi R, Russano M, Vaccaro V, Brunetti AE, Rotella V, Falcone A, Barbera MA, Corbelli J, Fasola G, Aglietta M, Zagonel V, Reni M, Vasile E, Brandi G. Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. Br J Cancer. 2014 Apr 29;110(9):2165-9. doi: 10.1038/bjc.2014.190. Epub 2014 Apr 8.</citation>
    <PMID>24714745</PMID>
  </reference>
  <reference>
    <citation>Lamarca A, Hubner RA, David Ryder W, Valle JW. Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol. 2014 Dec;25(12):2328-38. doi: 10.1093/annonc/mdu162. Epub 2014 Apr 25. Review.</citation>
    <PMID>24769639</PMID>
  </reference>
  <reference>
    <citation>Brieau B, Dahan L, De Rycke Y, Boussaha T, Vasseur P, Tougeron D, Lecomte T, Coriat R, Bachet JB, Claudez P, Zaanan A, Soibinet P, Desrame J, Thirot-Bidault A, Trouilloud I, Mary F, Marthey L, Taieb J, Cacheux W, Lièvre A. Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues. Cancer. 2015 Sep 15;121(18):3290-7. doi: 10.1002/cncr.29471. Epub 2015 Jun 5.</citation>
    <PMID>26052689</PMID>
  </reference>
  <reference>
    <citation>Kim BJ, Yoo C, Kim KP, Hyung J, Park SJ, Ryoo BY, Chang HM. Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. Br J Cancer. 2017 Feb 28;116(5):561-567. doi: 10.1038/bjc.2016.446. Epub 2017 Jan 12.</citation>
    <PMID>28081540</PMID>
  </reference>
  <reference>
    <citation>Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramírez J, Relling M, Chen P, Das S, Rosner GL, Ratain MJ. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol. 2009 Jun 1;27(16):2604-14. doi: 10.1200/JCO.2008.20.6300. Epub 2009 Apr 6.</citation>
    <PMID>19349540</PMID>
  </reference>
  <reference>
    <citation>Bellanti F, Kågedal B, Della Pasqua O. Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma? Eur J Clin Pharmacol. 2011 May;67 Suppl 1:87-107. doi: 10.1007/s00228-010-0966-3. Epub 2011 Feb 2. Review.</citation>
    <PMID>21287160</PMID>
  </reference>
  <reference>
    <citation>Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001 Aug;7(8):2182-94. Review.</citation>
    <PMID>11489791</PMID>
  </reference>
  <reference>
    <citation>Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991 Aug 15;51(16):4187-91.</citation>
    <PMID>1651156</PMID>
  </reference>
  <reference>
    <citation>Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res. 2002 Mar;8(3):641-61. Review.</citation>
    <PMID>11895891</PMID>
  </reference>
  <reference>
    <citation>Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol. 2001 Mar 1;19(5):1501-18. Review.</citation>
    <PMID>11230497</PMID>
  </reference>
  <reference>
    <citation>Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 2006 Mar 15;66(6):3271-7.</citation>
    <PMID>16540680</PMID>
  </reference>
  <reference>
    <citation>Kang MH, Wang J, Makena MR, Lee JS, Paz N, Hall CP, Song MM, Calderon RI, Cruz RE, Hindle A, Ko W, Fitzgerald JB, Drummond DC, Triche TJ, Reynolds CP. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression. Clin Cancer Res. 2015 Mar 1;21(5):1139-50. doi: 10.1158/1078-0432.CCR-14-1882.</citation>
    <PMID>25733708</PMID>
  </reference>
  <reference>
    <citation>Kalra AV, Kim J, Klinz SG, Paz N, Cain J, Drummond DC, Nielsen UB, Fitzgerald JB. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion. Cancer Res. 2014 Dec 1;74(23):7003-13. doi: 10.1158/0008-5472.CAN-14-0572. Epub 2014 Oct 1.</citation>
    <PMID>25273092</PMID>
  </reference>
  <reference>
    <citation>Tsai CS, Park JW, Chen LT. Nanovector-based therapies in advanced pancreatic cancer. J Gastrointest Oncol. 2011 Sep;2(3):185-94. doi: 10.3978/j.issn.2078-6891.2011.034.</citation>
    <PMID>22811849</PMID>
  </reference>
  <reference>
    <citation>Benson AB 3rd, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA Jr, McCallum R, Mitchell EP, O'Dorisio TM, Vokes EE, Wadler S. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004 Jul 15;22(14):2918-26.</citation>
    <PMID>15254061</PMID>
  </reference>
  <reference>
    <citation>Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT; NAPOLI-1 Study Group. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016 Feb 6;387(10018):545-57. doi: 10.1016/S0140-6736(15)00986-1. Epub 2015 Nov 29. Erratum in: Lancet. 2016 Feb 6;387(10018):536.</citation>
    <PMID>26615328</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2018</study_first_submitted>
  <study_first_submitted_qc>May 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2018</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Changhoon Yoo</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

